Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could an Iron-Removing pill protect the brain after a burst aneurysm?

NCT ID NCT03754725

First seen Nov 06, 2025 · Last updated Jun 23, 2026 · Updated 39 times

Summary

This study tests whether the drug deferiprone can safely lower iron levels in the brain after a bleeding aneurysm. About 66 adults who had a ruptured aneurysm will receive either deferiprone or a placebo for 14 days. Researchers will measure iron in spinal fluid, brain MRI scans, and memory tests to see if the drug helps prevent cognitive decline.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEMENTIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Duke University Health System

    RECRUITING

    Durham, North Carolina, 27710, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Univesity of Iowa Hospital and Clinics

    ACTIVE_NOT_RECRUITING

    Iowa City, Iowa, 52242, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Deferiprone (oral pill)

What this could lead to

If it works, this could point toward a treatment that reduces brain damage and memory loss after a bleeding aneurysm.

What could go wrong

This is an early Phase 1/2a trial with only 66 people, so it is too small to prove effectiveness. The drug may not reduce iron enough or could have side effects.

Conditions

The condition(s) this trial relates to.

acquired aneurysmal subarachnoid hemorrhage dementia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.